Last $0.47 USD
Change Today -0.003 / -0.64%
Volume 154.8K
IBIO On Other Exchanges
Symbol
Exchange
NYSE Amex
Berlin
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

ibio inc (IBIO) Snapshot

Open
$0.47
Previous Close
$0.47
Day High
$0.49
Day Low
$0.45
52 Week High
01/21/14 - $0.85
52 Week Low
10/11/13 - $0.28
Market Cap
30.5M
Average Volume 10 Days
206.0K
EPS TTM
$-0.12
Shares Outstanding
65.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IBIO INC (IBIO)

Related News

No related news articles were found.

ibio inc (IBIO) Related Businessweek News

No Related Businessweek News Found

ibio inc (IBIO) Details

iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of biologics; and iBioModulator, a technology platform that improves the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates include C1 Esterase Inhibitor, a preclinical stage plasma-derived protein; Alpha-Galactosidase, a preclinical orphan designation stage enzyme replacement; and Palivizumab, a preclinical stage monoclonal antibody for the therapeutic protein market. Its product candidates also comprise H1N1 Influenza and H5N1 Influenza viral disease vaccines that completed Phase I; Hookworm parasitic pathogen vaccine, which is in preclinical stage; and Human Papillomavirus therapeutic vaccine that is in preclinical stage. In addition, the company’s product candidates include Anthrax/Plague bacterial disease vaccine that is in preclinical stage; and Anthrax monoclonal antibody that is in preclinical stage for the Biodefense market. It has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor; an alliance with GE Healthcare to commercialize its plant-based technologies for the manufacture of biopharmaceuticals and vaccines; a collaboration agreement granting FioCruz/Bio-Manguinhos a license to use its proprietary technology in connection with the development, manufacture, and commercialization of vaccine products; and a license and collaboration agreement enabling Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. The company is headquartered in Newark, Delaware.

9 Employees
Last Reported Date: 09/30/13

ibio inc (IBIO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $300.0K
President
Total Annual Compensation: $230.0K
Chief Scientific Officer
Total Annual Compensation: $200.0K
Compensation as of Fiscal Year 2013.

ibio inc (IBIO) Key Developments

iBio Receives Patent Allowances for Pandemic Influenza Therapeutics

iBio has reported the allowance of two US patents for monoclonal antibodies targeting influenza. The antibodies covered by these patents are designed to block critical functions of the influenza virus necessary for infection or replication. iBioLaunch technology has previously been used for the development and successful Phase 1 clinical evaluation of vaccine candidates targeting H1N1 influenza and avian H5N1 influenza. The first newly allowed patent application, 'Human Neuraminidase Antibody and Methods of Use Thereof," includes claims for a monoclonal antibody against the influenza neuraminidase protein. Antibodies based on this invention are potential therapeutic agents against influenza, including highly pathogenic H5N1 strains resistant to drugs such as oseltamivir (marketed as Tamiflu®), and one such proprietary antibody, which is based upon iBio's iBioLaunch technology, has demonstrated safety and therapeutic efficacy in highly predictive animal models infected with a variety of influenza types, including H5N1. The second allowed patent application, "Influenza Hemagglutinin Antibodies, Compositions, and Related Methods," includes claims to an isolated monoclonal antibody or antigen-binding fragment that binds hemagglutinin (the viral protein that binds to susceptible cells as the first step in virus entry and infection) and where the antibody has a specified composition of matter. Interfering with hemagglutinin activity blocks further spread of the virus in the body. This invention is applicable to a wide range of influenza strains including the most dangerous types.

iBio, Inc. Presents at 26th Annual ROTH Conference, Mar-10-2014 05:30 PM

iBio, Inc. Presents at 26th Annual ROTH Conference, Mar-10-2014 05:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States.

iBio, Inc. Reports the Initiation of Phase 1 Human Safety and Immunogenicity Clinical Study of Transmission-Blocking Malaria Vaccine Candidate

iBio, Inc. reported the initiation of a Phase 1 human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. The vaccine candidate was produced on the company's proprietary iBioLaunch(TM) platform by the Fraunhofer USA Center for Molecular Biotechnology. Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer's plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBIO:US $0.47 USD -0.003

IBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IBIO.
View Industry Companies
 

Industry Analysis

IBIO

Industry Average

Valuation IBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.2x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IBIO INC, please visit www.ibioinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.